RE:RE:RE:RE:RE:News ReleaseHi Ingiboy. Yes, after a month of abstinence, I decided to have a peek at the Replicel Bulletin Board! It's hard to end this habit of self-abuse. I love the pain that the whip inflicts upon me!
I 100% agree with your assessment. Our CEO Denbrecker clearly has no empathy for the disappointments the small shareholders have experienced. His words are clearly meaningless. Haven't we heard him say 'there will be a number of exciting announcements in the near future' before? He is very proficient at 'copy and paste.' As an exercise in therapy, I am looking forward to voting against some of the passengers on the Board of Directors later this year.
I don't know if anyone has brought this up before but to me one of the issues with RCH-01 is the number of steps it takes to deliver the product to the customer (samples taken by doctor, delivered to lab, cultured in lab, sent back to doctor and injected in patients scalp - probably several times) and the disruption it will cause to doctors who do hair transplants. If a company has the rights to the USA for example, how many facilities would they need to culture the specimens from the customers? They would also need a lot of room to store these specimens for future use (perhaps a number of times over many years?). A successful RCH-01 is also going to affect doctors doing hair transplants in a major way - perhaps more patients but much less revenue per customer. I do not blame companies for not being enthusiastic about this concept.
The ideal solution for RCH-01 would be to identify the material in the dermal sheath cup which causes the hair to regrow and create a synthetic version which can work on anyone's dormant hair follicles. You could then sell it on prescription in a spray form and just apply it to the scalp - like Rogaine. The price of the stock would go through the roof if Replicel came up with this method of delivery. I would not be surprised if Shiseido is working on this now!
....Just my 14 cents worth!